Analysis of PFS2 by subsequent therapy in KEYNOTE-361: Pembrolizumab (pembro) plus chemotherapy (chemo) or pembro alone versus chemo as 1L therapy for advanced urothelial carcinoma (UC).

被引：0

作者：

Ozguroglu, Mustafa ^{[1
]}

Alva, Ajjai Shivaram ^{[2
]}

Csoszi, Tibor ^{[3
]}

Matsubara, Nobuaki ^{[4
]}

Geczi, Lajos ^{[5
]}

Cheng, Susanna Y. ^{[6
]}

Fradet, Yves ^{[7
]}

Oudard, Stephane ^{[8
]}

Vulsteke, Christof ^{[9
]}

Morales-Barrera, Rafael ^{[10
]}

Flechon, Aude ^{[11
]}

Gunduz, Seyda ^{[12
]}

Loriot, Yohann ^{[13
]}

Rodriguez-Vida, Alejo ^{[14
]}

Mamtani, Ronac ^{[15
]}

Yu, Evan Y. ^{[16
]}

Nam, Kijoeng ^{[17
]}

Imai, Kentaro ^{[17
]}

Moreno, Blanca Homet ^{[17
]}

Powles, Thomas ^{[18
]}

机构：

[1] Istanbul Univ Cerrahpasa, Cerrahpasa Med Sch, Istanbul, Turkey

[2] Univ Michigan, Rogel Canc Ctr, Ann Arbor, MI 48109 USA

[3] Hetenyi G Korhaz, Szolnok, Hungary

[4] Natl Canc Ctr Hosp East, Div Breast & Med Oncol, Chiba, Japan

[5] Natl Inst Oncol, Budapest, Hungary

[6] Sunnybrook Odette Canc Ctr, Toronto, ON, Canada

[7] Univ Laval, CHU Quebec, Quebec City, PQ, Canada

[8] Univ Paris, Hop Europeen Georges Pompidou, AP HP, Dept Oncol, Paris, France

[9] Univ Antwerp, Integrated Canc Ctr Ghent, Ctr Oncol Res CORE, Ghent, Belgium

[10] Vall dHebron Inst Oncol, Barcelona, Spain

[11] Ctr Leon Berard, Dept Med Oncol, Lyon, France

[12] Akdeniz Univ, Antalya, Turkey

[13] Univ Paris Saclay, Inst Gustave Roussy, Dept Canc Med, Villejuif, France

[14] Hosp del Mar Res Inst, Dept Med Oncol, Barcelona, Spain

[15] Univ Penn, Philadelphia, PA 19104 USA

[16] Univ Washington, Dept Med, Div Oncol, Seattle, WA 98195 USA

[17] Merck & Co Inc, Kenilworth, NJ USA

[18] Queen Mary Univ London, Barts Canc Inst, Barts Expt Canc Med Ctr, London, England

来源：

JOURNAL OF CLINICAL ONCOLOGY | 2021年 / 39卷 / 06期

关键词：

D O I：

10.1200/JCO.2021.39.6_suppl.448

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

448

引用

页数：4

共 50 条

[41] KEYNOTE-006 study of pembrolizumab (pembro) versus ipilimumab (ipi) for advanced melanoma: Efficacy by PD-L1 expression and line of therapy.
Daud, Adil
Blank, Christian U.
Robert, Caroline
Puzanov, Igor
Richtig, Erika
Margolin, Kim Allyson
O'Day, Steven
Nyakas, Marta
Lutzky, Jose
Tarhini, Ahmad A.
McWhirter, Elaine
Caglevic, Christian
Mohr, Peter
Millward, Michael
Butler, Marcus O.
Zhou, Honghong
Emancipator, Kenneth
Ebbinghaus, Scot
Ibrahim, Nageatte
Long, Georgina V.
JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
[42] KEYNOTE-756: Phase III study of neoadjuvant pembrolizumab (pembro) or placebo (pbo) plus chemotherapy (chemo), followed by adjuvant pembro or pbo plus endocrine therapy (ET) for early-stage high-risk ER+/HER2e breast cancer
Cardoso, F.
McArthur, H. L.
Schmid, P.
Cortes, J.
Harbeck, N.
Telli, M. L.
Cescon, D. W.
O'Shaughnessy, J.
Fasching, P.
Shao, Z.
Loirat, D.
Park, Y. H.
Fernandez, M. E. Gonzalez
Liu, Z.
Yasojima, H.
Ding, Y.
Jia, L.
Karantza, V. V.
Tryfonidis, K. E.
Bardia, A.
ANNALS OF ONCOLOGY, 2023, 34 : S1260 - S1261
[43] First-line (1L) maintenance therapy with niraparib (nira) plus pembrolizumab (pembro) vs placebo plus pembro in advanced/metastatic non-small cell lung cancer (NSCLC): Phase 3 ZEAL-1L study
Nagrial, Adnan
Ramalingam, Suresh S.
de Castro, Gilberto, Jr.
Garassino, Marina Chiara
Mazieres, Julien
Sanborn, Rachel
Smit, Egbert
Spigel, David R.
Thomas, Michael
Velcheti, Vamsidhar
Shi, Lei
Neibauer, Melissa Whipple
Stojadinovic, Alexander
Peters, Solange
ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, 2021, 17 : 204 - 205
[44] First-line (1L) maintenance therapy with niraparib (nira) plus pembrolizumab (pembro) vs placebo plus pembro in advanced/metastatic non-small cell lung cancer (NSCLC): Phase III ZEAL-1L study
Ramalingam, S. S.
de Castro, G., Jr.
Garassino, M. C. C.
Mazieres, J.
Sanborn, R. E.
Smit, E. F. F.
Spigel, D. R.
Thomas, M.
Velcheti, V.
Zhi, E.
Whipple Neibauer, M.
Stojadinovic, A.
Peters, S.
ANNALS OF ONCOLOGY, 2021, 32 : S1030 - S1032
[45] Results from phase 3 KEYLYNK-008: Pembrolizumab (pembro) with and without maintenance olaparib (ola) after first-line (1L) pembro plus chemotherapy (chemo) for metastatic squamous non-small-cell lung cancer (sqNSCLC)
Hochmair, Maximilian
Schenker, Michael
Dols, Manuel Cobo
Kim, Tae Min
Kim, Sang-We
Ozyilkan, Ozgur
Smagina, Maria
Viktoriya, Leonova
Kato, Terufumi
Fedenko, Alexander
De Angelis, Flavia
Rittmeyer, Achim
Gray, Jhanelle E.
Greystoke, Alastair
Huang, Qinlei
Zhao, Bin
Lara-Guerra, Humberto
Nadal, Ernest
CANCER RESEARCH, 2024, 84 (07)
[46] Results from KEYNOTE-B99: Phase 2 study of first-line (1L) pembrolizumab (pembro) plus investigational agents and chemotherapy (chemo) for extensive-stage small-cell lung cancer (ES-SCLC)
Rodriguez-Abreu, Delvys
Hochmair, Maximillian
Cho, Byoung Chul
Csoszi, Tibor
Kutiel, Talia Shentzer
Mueller, Veronika
Ahn, Myung-Ju
Kowalski, Dariusz
Maio, Michele
Moiseyenko, Vladimir
Navarro, Alejandro
Niu, Jianxin
Fung, Andrea S.
Lips, Carolin
Zhou, Heng
Zhao, Bin
Lara-Guerra, Humberto
Peled, Nir
CANCER RESEARCH, 2024, 84 (07)
[47] Pembrolizumab (pembro) versus platinum-based chemotherapy (chemo) as first-line therapy for advanced/metastatic NSCLC with a PD-L1 tumor proportion score (TPS) ≥ 1%: Open-label, phase 3 KEYNOTE-042 study.
Lopes, Gilberto
Wu, Yi-Long
Kudaba, Iveta
Kowalski, Dariusz
Cho, Byoung Chul
Castro, Gilberto
Srimuninnimit, Vichien
Bondarenko, Igor
Kubota, Kaoru
Lubiniecki, Gregory M.
Zhang, Jin
Kush, Debra A.
Mok, Tony
JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (18)
[48] Pembrolizumab (pembro) plus axitinib (axi) versus sunitinib as first-line therapy for locally advanced or metastatic renal cell carcinoma (mRCC): phase Ill KEYNOTE-426 study.
Powles, Thomas
Plimack, Elizabeth R.
Stus, Viktor
Gafanov, Rustem Airatovich
Hawkins, Robert E.
Nosov, Dmitry
Pouliot, Frederic
Alekseev, Boris Yakovlevich
Soulieres, Denis
Melichar, Bohuslav
Vynnychenko, Ihor
Kryzhanivska, Anna
Bondarenko, Igor
Azevedo, Sergio Jobim
Borchiellini, Delphine
Shou, Qiong
Perini, Rodolfo F.
Chen, Mei
Atkins, Michael B.
Rini, Brian I.
JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (07)
[49] KEYNOTE-555 Cohort B: Efficacy, safety, and PK of pembrolizumab (pembro) 400 mg every 6 weeks (Q6W) as 1L therapy for advanced melanoma.
Jacobs, Conrad R.
Rapoport, Bernardo Leon
Chan, Sze Wai
Ruff, Paul
Arance, Ana Maria
Mujika, Karmele
Anderson, James Robert
Lala, Mallika
Jain, Lokesh
Akala, Omobolaji Oyekunle
Chartash, Elliot
Cohen, Graham Lawrence
JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
[50] Pembrolizumab (pembro) plus carboplatin (carbo) plus paclitaxel (pacli) as first-line (1L) therapy in recurrent/metastatic (R/M) head and neck squamous cell carcinoma (HNSCC): Phase VI KEYNOTE-B10 study
Dzienis, M. R.
Cundom, J. E.
Fuentes, C. S.
Hansen, A. R.
Nordlinger, M. J.
Pastor, A. V.
Oppelt, P.
Neki, A.
Gregg, R. W.
Lima, I. P. F.
Franke, F. A.
Da Cunha Junior, G. F.
Tseng, J. E.
Loree, T.
Joshi, A. J.
Mccarthy, J. S.
Naicker, N.
Sidi, Y.
Gumuscu, B.
De Castro, G., Jr.
ANNALS OF ONCOLOGY, 2022, 33 (07) : S839 - S840

← 1 2 3 4 5 →